Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VALUE-Dx

Financiado

Cerrado

The value of diagnostics to combat antimicrobial resistance by optimising antibi...

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a ne... ver más

30/09/2024

Líder desconocido

14M€

Presupuesto del proyecto: 14M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Ver 29 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

IMI2-2017-13-03: The value of diagnostics to combat... Specific Challenge:Huge amounts of antibiotics are prescribed and consumed unnecessarily in almost a...

I+D

Cerrada hace 7 años

0% 48% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

29 Participantes

GALVANIZADORA VALENCIANA

ABBOTT RAPID DX INTERNATIONA...

EUROPEAN RESPIRATORY SOCIETY

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 66 meses Fecha Inicio: 2019-03-25
Fecha Fin: 2024-09-30

Líder del proyecto Líder desconocido

Presupuesto del proyecto 14M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice. VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests. A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores